Torrent Pharma gets USFDA OAI status for Gujarat facility
Ahmedabad: Torrent Pharma has announced that the Company has received a communication from the US Food and Drug Administration (USFDA) determining the inspection classification of the manufacturing facility at Indrad, Gujarat as “Official Action Indicated” (OAI).
Official Action Indicated (OAI) which means regulatory and/or administrative actions will be recommended.
Medical Dialogues team had earlier reported that the USFDA had issued a "Form 483" with 3 observations at the end of the inspection at Torrent Pharma's manufacturing facility at Indrad, Gujarat.
Torrent Pharma is an Indian multinational pharmaceutical company headquartered in Ahmedabad, India. The company specializes in the therapeutic segments of cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology, and anti-infective segments. The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
Read also: Torrent Pharma to buy Curatio Healthcare for Rs 2,000 crores
